Chisanga Mwape
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chisanga Mwape has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Afnan Ahmad Qureshi
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
2 shared publications - Aleeza Fatima
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
2 shared publications - Huzaifa Mahmood
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
2 shared publications - Muhammad Zaid Saeed
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
2 shared publications - Abdul Moiz Khan
Department of Internal Medicine, Ayub Medical College, Abbottabad, Pakistan
1 shared publication - Ailiya Batool
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication
Latest Publications
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3870-3871
Ending Lassa neglect: the urgent case for a licensed vaccine
Lassa fever is an endemic viral hemorrhagic disease in West Africa with significant morbidity and mortality, yet it remains inadequately addressed in global health priorities. First identified in Nigeria in 1969, the disease continues to affect an estimated 100 000–300 000 individuals annually, with high case fatality rates among hospitalized patients and vulnerable populations. Despite its substantial burden and recurrent seasonal outbreaks, particularly in Nigeria, major gaps persist in both prevention and treatment strategies. Notably, there is no licensed vaccine available more than five decades after its discovery, and current therapeutic practices rely heavily on ribavirin, a drug supported by limited and methodologically weak evidence. Recent years have witnessed encouraging developments, including early-phase vaccine trials and large-scale epidemiological initiatives such as the ENABLE study, alongside coordinated efforts to establish adaptive clinical trial platforms. However, these advancements remain insufficient without sustained funding, robust clinical trial infrastructure, and policy-level commitment. This letter highlights the urgent need to accelerate vaccine development, reassess existing treatment guidelines, and strengthen outbreak preparedness in endemic regions. Addressing these gaps is critical to transitioning from reactive outbreak response to proactive and evidence-based disease control, ultimately reducing the burden of Lassa fever and improving global health equity.
- 21 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3870-3871
Open AccessEnding Lassa neglect: the urgent case for a licensed vaccine
Lassa fever is an endemic viral hemorrhagic disease in West Africa with significant morbidity and mortality, yet it remains inadequately addressed in global health priorities. First identified in Nigeria in 1969, the disease continues to affect an estimated 100 000–300 000 individuals annually, with high case fatality rates among hospitalized patients and vulnerable populations. Despite its substantial burden and recurrent seasonal outbreaks, particularly in Nigeria, major gaps persist in both prevention and treatment strategies. Notably, there is no licensed vaccine available more than five decades after its discovery, and current therapeutic practices rely heavily on ribavirin, a drug supported by limited and methodologically weak evidence. Recent years have witnessed encouraging developments, including early-phase vaccine trials and large-scale epidemiological initiatives such as the ENABLE study, alongside coordinated efforts to establish adaptive clinical trial platforms. However, these advancements remain insufficient without sustained funding, robust clinical trial infrastructure, and policy-level commitment. This letter highlights the urgent need to accelerate vaccine development, reassess existing treatment guidelines, and strengthen outbreak preparedness in endemic regions. Addressing these gaps is critical to transitioning from reactive outbreak response to proactive and evidence-based disease control, ultimately reducing the burden of Lassa fever and improving global health equity.
- Open Access
- 10 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1144-1145
AMT-130 gene therapy: a promising disease-modifying approach for Huntington’s disease
Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by expanded Cytosine-Adenine-GuanineCAG repeats in the huntingtin (HTT) gene, leading to the production and accumulation of mutant huntingtin protein and subsequent neuronal dysfunction and loss. Current management remains largely symptomatic, with no established disease-modifying therapy. AMT-130 represents a novel and promising approach aimed at directly targeting the underlying molecular pathology of HD. AMT-130 is a one-time gene therapy that utilizes an adeno-associated virus serotype 5 (AAV5) vector to deliver an engineered microRNA (miHTT) into the caudate and putamen via stereotactic intracerebral infusion. This microRNA selectively reduces HTT mRNA levels, resulting in sustained lowering of mutant huntingtin protein. Preclinical studies in both large-animal and rodent models have demonstrated broad vector distribution, long-term expression, significant reduction in huntingtin levels, improved motor performance, decreased neuronal degeneration, and prolonged survival. Early Phase I/II clinical data indicate a favorable safety profile, reductions in neurofilament light chain levels, and stabilization of motor and functional decline, particularly in high-dose cohorts, suggesting a potential slowing of disease progression. While long-term efficacy and broader clinical validation are still required, AMT-130 shows strong potential to shift HD treatment from purely symptomatic care toward meaningful disease modification. Its success may also pave the way for microRNA-based therapies in other neurodegenerative disorders.
- 10 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1144-1145
Open AccessAMT-130 gene therapy: a promising disease-modifying approach for Huntington’s disease
Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by expanded Cytosine-Adenine-GuanineCAG repeats in the huntingtin (HTT) gene, leading to the production and accumulation of mutant huntingtin protein and subsequent neuronal dysfunction and loss. Current management remains largely symptomatic, with no established disease-modifying therapy. AMT-130 represents a novel and promising approach aimed at directly targeting the underlying molecular pathology of HD. AMT-130 is a one-time gene therapy that utilizes an adeno-associated virus serotype 5 (AAV5) vector to deliver an engineered microRNA (miHTT) into the caudate and putamen via stereotactic intracerebral infusion. This microRNA selectively reduces HTT mRNA levels, resulting in sustained lowering of mutant huntingtin protein. Preclinical studies in both large-animal and rodent models have demonstrated broad vector distribution, long-term expression, significant reduction in huntingtin levels, improved motor performance, decreased neuronal degeneration, and prolonged survival. Early Phase I/II clinical data indicate a favorable safety profile, reductions in neurofilament light chain levels, and stabilization of motor and functional decline, particularly in high-dose cohorts, suggesting a potential slowing of disease progression. While long-term efficacy and broader clinical validation are still required, AMT-130 shows strong potential to shift HD treatment from purely symptomatic care toward meaningful disease modification. Its success may also pave the way for microRNA-based therapies in other neurodegenerative disorders.